155 related articles for article (PubMed ID: 16298993)
1. Solution structure of the human ubiquitin-specific protease 15 DUSP domain.
de Jong RN; Ab E; Diercks T; Truffault V; Daniëls M; Kaptein R; Folkers GE
J Biol Chem; 2006 Feb; 281(8):5026-31. PubMed ID: 16298993
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
3. The COP9/signalosome increases the efficiency of von Hippel-Lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-alpha ubiquitination.
Miyauchi Y; Kato M; Tokunaga F; Iwai K
J Biol Chem; 2008 Jun; 283(24):16622-31. PubMed ID: 18424433
[TBL] [Abstract][Full Text] [Related]
4. Structural and Functional Characterization of Ubiquitin Variant Inhibitors of USP15.
Teyra J; Singer AU; Schmitges FW; Jaynes P; Kit Leng Lui S; Polyak MJ; Fodil N; Krieger JR; Tong J; Schwerdtfeger C; Brasher BB; Ceccarelli DFJ; Moffat J; Sicheri F; Moran MF; Gros P; Eichhorn PJA; Lenter M; Boehmelt G; Sidhu SS
Structure; 2019 Apr; 27(4):590-605.e5. PubMed ID: 30713027
[TBL] [Abstract][Full Text] [Related]
5. Structure of the USP15 N-terminal domains: a β-hairpin mediates close association between the DUSP and UBL domains.
Harper S; Besong TM; Emsley J; Scott DJ; Dreveny I
Biochemistry; 2011 Sep; 50(37):7995-8004. PubMed ID: 21848306
[TBL] [Abstract][Full Text] [Related]
6. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
7. Identification of Elongin C and Skp1 sequences that determine Cullin selection.
Yan Q; Kamura T; Cai Y; Jin J; Ivan M; Mushegian A; Conaway RC; Conaway JW
J Biol Chem; 2004 Oct; 279(41):43019-26. PubMed ID: 15280393
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
[TBL] [Abstract][Full Text] [Related]
9. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
Biochem Biophys Res Commun; 2002 Jun; 294(3):700-9. PubMed ID: 12056827
[TBL] [Abstract][Full Text] [Related]
10. Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
Pereira T; Zheng X; Ruas JL; Tanimoto K; Poellinger L
J Biol Chem; 2003 Feb; 278(9):6816-23. PubMed ID: 12468553
[TBL] [Abstract][Full Text] [Related]
11. A Panel of Engineered Ubiquitin Variants Targeting the Family of Domains Found in Ubiquitin Specific Proteases (DUSPs).
Tang JQ; Veggiani G; Singer A; Teyra J; Chung J; Sidhu SS
J Mol Biol; 2021 Dec; 433(24):167300. PubMed ID: 34666042
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
13. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
Corn PG; McDonald ER; Herman JG; El-Deiry WS
Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
[TBL] [Abstract][Full Text] [Related]
14. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau.
Lee C; Kim SJ; Jeong DG; Lee SM; Ryu SE
J Biol Chem; 2003 Feb; 278(9):7558-63. PubMed ID: 12482756
[TBL] [Abstract][Full Text] [Related]
15. Structural variability of the ubiquitin specific protease DUSP-UBL double domains.
Elliott PR; Liu H; Pastok MW; Grossmann GJ; Rigden DJ; Clague MJ; Urbé S; Barsukov IL
FEBS Lett; 2011 Nov; 585(21):3385-90. PubMed ID: 22001210
[TBL] [Abstract][Full Text] [Related]
16. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
Paltoglou S; Roberts BJ
Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
[TBL] [Abstract][Full Text] [Related]
19. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors.
Cai QL; Knight JS; Verma SC; Zald P; Robertson ES
PLoS Pathog; 2006 Oct; 2(10):e116. PubMed ID: 17069461
[TBL] [Abstract][Full Text] [Related]
20. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
